Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Norepinephrine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
NuLiv's Verbasnol Reduces Acne And Improves Skin Quality in Study
Details : Norepinephrine is an adrenergic receptor agonist, small molecule drug candidate. Diluted with sodium chloride solution the treatment of severe, acute hypotension.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 22, 2024
Lead Product(s) : Norepinephrine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AstraGin
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NuLiv Science demonstrate the potential of AstraGin® to support overall gut health and well-being, positioning it as a promising solution for individuals with UC and other gut-related challenges.
Brand Name : AstraGin
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 03, 2023
Lead Product(s) : AstraGin
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?